We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis.
- Authors
Andrade, Fabia de Oliveira; Furtado, Kelly Silva; Heidor, Renato; Sandri, Silvana; Hebeda, Cristina Bichels; Miranda, Mayara Lilian Paulino; Fernandes, Laura Helena Gasparini; Yamamoto, Roberto Carvalho; Horst, Maria Aderuza; Farsky, Sandra Helena Poliselli; Moreno, Fernando Salvador
- Abstract
Agents that inhibit angiogenic factors may prevent the development of hepatocellular carcinoma (HCC). Thus, the objective of this study was to kinetically evaluate the antiangiogenic activity of tributyrin (TB), a butyric acid prodrug, in the promotion stage of hepatocarcinogenesis. For this purpose, the resistant hepatocyte (RH) model was used for induction of preneoplastic lesions in Wistar rats. During the promotion phase, the animals received TB or maltodextrin (MD) as control daily. The rats were killed at three time-points (P1, P2 and P3). Increased expression of Vegfa and Vegfr2 was observed during promotion phase of hepatocarcinogenesis, which was not reversed by TB treatment. However, TB treatment reduced the expression of cluster of differentiation (CD) 34-positive vessels at P3 and α-smooth muscle actin (α-SMA)-positive vessels at P2 compared with MD. Enhanced levels of hypoxia inducible factor-1α (HIF-1α) and phosphorylated extracellular signal-regulated kinases (pERK) were detected at P3 when compared with P1 and P2 in the MD treatment. TB treatment reduced the levels of HIF-1α and pERK at P3 relative to the MD control. Experiments with human umbilical vein endothelial cells (HUVEC) showed that sodium butyrate (NaBu) inhibited cell migration and tube formation, confirming the antiangiogenic activity of its prodrug TB. In conclusion, antiangiogenic activity of TB is an early event that already occurs in preneoplastic livers, reinforcing its potential chemopreventive effects against HCC.
- Subjects
BUTYRIC acid; PRODRUGS; EXTRACELLULAR signal-regulated kinases; SODIUM butyrate; VASCULAR endothelial growth factors; PRECANCEROUS conditions
- Publication
Carcinogenesis, 2019, Vol 40, Issue 8, p979
- ISSN
0143-3334
- Publication type
Article
- DOI
10.1093/carcin/bgy190